Study investigating if finger-prick blood test could diagnose early-stage Alzheimer’s disease
The Bio-Hermes-002 study is investigating if a finger-prick blood test could diagnose early-stage Alzheimer’s disease before symptoms begin.
Bio-Hermes-002 will involve 1,000 people in the UK, USA and Canada (including at least 25% of participants from under-represented communities / non-white backgrounds) and will explore if a finger-prink blood test could be used widely to provide a faster and more accessible route to diagnosis than current methods.
Bio-Hermes-002 researchers will check blood samples for the presence of three key proteins often found in the brains of people with Alzheimer’s – pTau217, GFAP and NfL. They will then compare the finger-prick blood test result to current diagnostic testing for Alzheimer’s disease.
The study, which is being led by LifeArc and the Global Alzheimer’s Platform Foundation (GAP) – with support from the UK Dementia Research Institute (UK DRI) – is expected to complete in 2028.
Find out more about the study here: https://www.ukdri.ac.uk/news-and-events/scientists-test-whether-finger-prick-blood-test-could-help-diagnose-alzheimers
Information about recruitment onto this study can be found here: https://globalalzplatform.org/biohermes-002study/